Updates

EMIS

April 2021

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

EMIS has been a longstanding hold for GP3 - solid enough but as yet no cigar. Latest full year results show flattish sales, pretax profit and eps at £159.5m, £39.5m and 51p, respectively. Net cash has ballooned by £21.9m to £53m or 84p a share (albeit flattered by £7.3m from deferred VAT).Much of the statement is what you expect to see - EMIS is maintaining huge market shares amongst GPs, pharmacies and social care for its mission critical systems, and recurring revenue has also inched up to £130m or 82% of sales. The Health side saw a once off boost of additional hardware sales of c£4-£5m as GPs enhanced their capability for home working but set against that there was a dearth of the “non recurring” project work it might usually h ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

IDOX

Eagle Eye

EMIS - Buys FourteenFish for £15.8m (April 2022)

EMIS (February 2022)

EMIS (October 2021)

EMIS - Shares power ahead as trading strengthens (September 2021)

EMIS (March 2021)

EMIS - Cash balloons to £44m and deals planned (October 2020)

EMIS (August 2020)

EMIS - Place confirmed on GP IT Futures framework (November 2019)

EMIS - Sells non-core retinopathy business (May 2019)

EMIS - 220 now working towards a new version of clinical management system EMIS-X (April 2019)

EMIS (December 2018)

EMIS - Meeting notes (October 2018)

EMIS - Cash climbs to £32m (August 2018)

EMIS - 53.5p eps forecast for next year (April 2018)

EMIS (February 2018)

EMIS (August 2017)

EMIS - To invest £7m in patient.info (April 2017)

Emis (November 2016)

EMIS (August 2016)

EMIS (April 2016)

EMIS (February 2016)

EMIS - Higher margins than Kainos (November 2015)

EMIS - Well set for a big beat on forecasts (October 2015)

EMIS - 75% of revenues repeat (April 2015)

Emis - Sales up 30% with double digit organic growth (February 2015)

Emis - Buys retinopathy screening business (September 2013)

Emis (February 2013)

Emis - Rollout of EMISWeb accelerates (September 2012)

Emis (April 2012)

EMIS (January 2012)

EMIS - 2091 "familiarisation" orders (September 2011)

EMIS - Penetration of EMIS Web Continues (August 2011)

EMIS - Recurring revenues grow to 81% (April 2011)

EMIS - Slow but sure rollout of EMIS Web (March 2011)

EMIS (October 2010)

EMIS (July 2010)

EMIS Group - EMISWeb launch imminent (June 2010)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X

EMIS

April 2021

Related Articles

LIMITED PERIOD OFFER

SUBSCRIBE TODAY AND SAVE £40 WITH OFFER CODE 40OFFSCSW